scholarly journals Bayesian Error Analysis for Feature Selection in Biomarker Discovery

IEEE Access ◽  
2019 ◽  
Vol 7 ◽  
pp. 127544-127563
Author(s):  
Ali Foroughi Pour ◽  
Lori A. Dalton
Keyword(s):  
Feature Selection ◽  
Error Analysis ◽  
Biomarker Discovery

scholarly journals Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Joe W. Chen ◽  
Joseph Dhahbi
Keyword(s):  
Gene Expression ◽  
Feature Selection ◽  
Expression Analysis ◽  
Gene Expression Analysis ◽  
Biomarker Discovery ◽  
Lung Squamous Cell Carcinoma ◽  
Cancer Classification ◽  
Selection Methods ◽  
Biomarker Identification ◽  
Overlapping Method

AbstractLung cancer is one of the deadliest cancers in the world. Two of the most common subtypes, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), have drastically different biological signatures, yet they are often treated similarly and classified together as non-small cell lung cancer (NSCLC). LUAD and LUSC biomarkers are scarce, and their distinct biological mechanisms have yet to be elucidated. To detect biologically relevant markers, many studies have attempted to improve traditional machine learning algorithms or develop novel algorithms for biomarker discovery. However, few have used overlapping machine learning or feature selection methods for cancer classification, biomarker identification, or gene expression analysis. This study proposes to use overlapping traditional feature selection or feature reduction techniques for cancer classification and biomarker discovery. The genes selected by the overlapping method were then verified using random forest. The classification statistics of the overlapping method were compared to those of the traditional feature selection methods. The identified biomarkers were validated in an external dataset using AUC and ROC analysis. Gene expression analysis was then performed to further investigate biological differences between LUAD and LUSC. Overall, our method achieved classification results comparable to, if not better than, the traditional algorithms. It also identified multiple known biomarkers, and five potentially novel biomarkers with high discriminating values between LUAD and LUSC. Many of the biomarkers also exhibit significant prognostic potential, particularly in LUAD. Our study also unraveled distinct biological pathways between LUAD and LUSC.

scholarly journals A Critical Assessment of Feature Selection Methods for Biomarker Discovery in Clinical Proteomics

2012 ◽  
Vol 12 (1) ◽  
pp. 263-276 ◽  
Author(s):  
Christin Christin ◽  
Huub C. J. Hoefsloot ◽  
Age K. Smilde ◽  
B. Hoekman ◽  
Frank Suits ◽  
...  
Keyword(s):  
Feature Selection ◽  
Biomarker Discovery ◽  
Critical Assessment ◽  
Clinical Proteomics ◽  
Selection Methods

scholarly journals Robust biomarker discovery for hepatocellular carcinoma from high-throughput data by multiple feature selection methods

2021 ◽  
Vol 14 (S1) ◽  
Author(s):  
Zishuang Zhang ◽  
Zhi-Ping Liu
Keyword(s):  
Machine Learning ◽  
Hepatocellular Carcinoma ◽  
Feature Selection ◽  
High Throughput ◽  
Biomarker Discovery ◽  
Selection Process ◽  
Recursive Feature Elimination ◽  
Statistical Interpretation ◽  
Cancer Data ◽  
High Throughput Data

Abstract Background Hepatocellular carcinoma (HCC) is one of the most common cancers. The discovery of specific genes severing as biomarkers is of paramount significance for cancer diagnosis and prognosis. The high-throughput omics data generated by the cancer genome atlas (TCGA) consortium provides a valuable resource for the discovery of HCC biomarker genes. Numerous methods have been proposed to select cancer biomarkers. However, these methods have not investigated the robustness of identification with different feature selection techniques. Methods We use six different recursive feature elimination methods to select the gene signiatures of HCC from TCGA liver cancer data. The genes shared in the six selected subsets are proposed as robust biomarkers. Akaike information criterion (AIC) is employed to explain the optimization process of feature selection, which provides a statistical interpretation for the feature selection in machine learning methods. And we use several methods to validate the screened biomarkers. Results In this paper, we propose a robust method for discovering biomarker genes for HCC from gene expression data. Specifically, we implement recursive feature elimination cross-validation (RFE-CV) methods based on six different classication algorithms. The overlaps in the discovered gene sets via different methods are referred as the identified biomarkers. We give an interpretation of the feature selection process based on machine learning using AIC in statistics. Furthermore, the features selected by the backward logistic stepwise regression via AIC minimum theory are completely contained in the identified biomarkers. Through the classification results, the superiority of interpretable robust biomarker discovery method is verified. Conclusions It is found that overlaps among gene subsets contain different quantitative features selected by the RFE-CV of 6 classifiers. The AIC values in the model selection provide a theoretical foundation for the feature selection process of biomarker discovery via machine learning. What’s more, genes containing in more optimally selected subsets make better biological sense and implication. The quality of feature selection is improved by the intersections of biomarkers selected from different classifiers. This is a general method suitable for screening biomarkers of complex diseases from high-throughput data.

scholarly journals Biomarker discovery in inflammatory bowel diseases using network-based feature selection

PLoS ONE ◽  
2019 ◽  
Vol 14 (11) ◽  
pp. e0225382 ◽  
Author(s):  
Mostafa Abbas ◽  
John Matta ◽  
Thanh Le ◽  
Halima Bensmail ◽  
Tayo Obafemi-Ajayi ◽  
...  
Keyword(s):  
Feature Selection ◽  
Inflammatory Bowel Diseases ◽  
Biomarker Discovery ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals A random forest based biomarker discovery and power analysis framework for diagnostics research

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Animesh Acharjee ◽  
Joseph Larkman ◽  
Yuanwei Xu ◽  
Victor Roth Cardoso ◽  
Georgios V. Gkoutos
Keyword(s):  
Feature Selection ◽  
Random Forest ◽  
Translational Medicine ◽  
Power Analysis ◽  
Biomarker Discovery ◽  
Feature Selection Method ◽  
Correction Method ◽  
Web Interface ◽  
Biomarker Identification ◽  
Future Studies

Abstract Background Biomarker identification is one of the major and important goal of functional genomics and translational medicine studies. Large scale –omics data are increasingly being accumulated and can provide vital means for the identification of biomarkers for the early diagnosis of complex disease and/or for advanced patient/diseases stratification. These tasks are clearly interlinked, and it is essential that an unbiased and stable methodology is applied in order to address them. Although, recently, many, primarily machine learning based, biomarker identification approaches have been developed, the exploration of potential associations between biomarker identification and the design of future experiments remains a challenge. Methods In this study, using both simulated and published experimentally derived datasets, we assessed the performance of several state-of-the-art Random Forest (RF) based decision approaches, namely the Boruta method, the permutation based feature selection without correction method, the permutation based feature selection with correction method, and the backward elimination based feature selection method. Moreover, we conducted a power analysis to estimate the number of samples required for potential future studies. Results We present a number of different RF based stable feature selection methods and compare their performances using simulated, as well as published, experimentally derived, datasets. Across all of the scenarios considered, we found the Boruta method to be the most stable methodology, whilst the Permutation (Raw) approach offered the largest number of relevant features, when allowed to stabilise over a number of iterations. Finally, we developed and made available a web interface (https://joelarkman.shinyapps.io/PowerTools/) to streamline power calculations thereby aiding the design of potential future studies within a translational medicine context. Conclusions We developed a RF-based biomarker discovery framework and provide a web interface for our framework, termed PowerTools, that caters the design of appropriate and cost-effective subsequent future omics study.

Sign in / Sign up

Export Citation Format

Share Document